Pacific Biosciences Of California (PACB) closed at $2.90 on October 29, 2026, up 2.5% from the previous close, on volume of 11,575,989 shares (30-day average 17,142,353).
Data as of October 29, 2026.
PacBio Highlights Three November Investor Events, With Two Fireside Chats Set for Webcast
Market Chameleon (Wed, 28-Oct 7:35 AM ET)
PacBio to Participate in Upcoming Investor Conferences
Globe Newswire (Tue, 27-Oct 4:05 PM ET)
Globe Newswire (Mon, 19-Oct 9:05 AM ET)
PacBio to Report Third Quarter 2026 Financial Results on November 4, 2026
Globe Newswire (Wed, 14-Oct 4:05 PM ET)
PacBio and TychoBio Collaborate to Train AI Models for Rare Disease RNA Therapeutics
Globe Newswire (Tue, 6-Oct 9:05 AM ET)
PacBio to Participate in the Morgan Stanley 24?? Annual Global Healthcare Conference
Globe Newswire (Thu, 3-Sep 4:05 PM ET)
PacBio Appoints Mark Van Oene as President and Chief Executive Officer
Globe Newswire (Wed, 5-Aug 4:08 PM ET)
PacBio Announces Second Quarter 2026 Financial Results
Globe Newswire (Wed, 5-Aug 4:05 PM ET)
Globe Newswire (Wed, 5-Aug 9:05 AM ET)
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
Pacific Biosciences Of California trades on the NASDAQ stock market under the symbol PACB.
As of October 29, 2026, PACB stock price climbed to $2.90 with 11,575,989 million shares trading.
PACB has a beta of 1.20, meaning it tends to be more sensitive to market movements. PACB has a correlation of 0.02 to the broad based SPY ETF.
PACB has a market cap of $901.41 million. This is considered a Small Cap stock.
Last quarter Pacific Biosciences Of California reported $39 million in Revenue and -$.14 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$.01.
In the last 3 years, PACB traded as high as $10.65 and as low as $.85.
The top ETF exchange traded funds that PACB belongs to (by Net Assets): ARKE, ARKK, ARKG, VTI, IWM.
PACB has outperformed the market in the last year with a price return of +47.2% while the SPY ETF gained +13.1%. PACB has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +108.6% and +45.7%, respectively, while the SPY returned +4.1% and 0.0%, respectively.
PACB support price is $2.60 and resistance is $3.06 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PACB shares will trade within this expected range on the day.
